ASPHO 2020 - CANCELLED: American Society of Pediatric Hematology / Oncology Annual Meeting
May 06 - May 09, 2020 | Fort WorthTXUS
LARVOL is not affiliated with CANCELLED: American Society of Pediatric Hematology / Oncology Annual Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 14 abstracts linked to Trials
CLR 131 IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC MALIGNANCIES
LAROTRECTINIB EFFICACY AND SAFETY IN PEDIATRIC PATIENTS WITH TRK FUSION CANCER
LENTIGLOBIN GENE THERAPY FOR PATIENTS WITH SICKLE CELL DISEASE: UPDATED RESULTS FROM STUDY HGB-206
LENTIGLOBIN GENE THERAPY IN PEDIATRICS, ADOLESCENTS, ADULTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA
PILOT STUDY OF APIXABAN IN SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN PEDIATRIC PATIENTS
PREDICTIVE PHARMACOKINETIC MODEL OF EMAPALUMAB PLASMA CONCENTRATIONS IN HEALTHY VOLUNTEERS
PRELIMINARY SAFETY RESULTS OF DEFIBROTIDE IN SCD PATIENTS WITH ACUTE CHEST SYNDROME (IND 127812)
PROSPECTIVE TRIAL OF IBRUTINIB IN CHILDREN WITH CHRONIC GRAFT VERSUS HOST DISEASE
ROLE OF TYROSINE KINASE INHIBITORS IN CHILDREN WITH MEN2 ASSOCIATED MEDULLARY THYROID CARCINOMA
TISAGENLECLEUCEL MANUFACTURING IN PATIENTS < 3 YEARS OF AGE WITH R/R ACUTE LYMPHOBLASTIC LEUKEMIA.
VOXELOTOR IN CHILDREN WITH SICKLE CELL ANEMIA: EFFICACY AND IMPROVEMENT IN ERYTHROCYTE PHYSIOLOGY
REDUCED FREQUENCY OF MAINTENANCE PULSES IN STANDARD-RISK B ACUTE LYMPHOBLASTIC LEUKEMIA AALL0932
SELUMETINIB IN CHILDREN WITH CLINICALLY ASYMPTOMATIC INOPERABLE NF1 RELATED PLEXIFORM NEUROFIBROMAS
A Randomized Phase 3 Trial of Blinatumomab vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children’s Oncology Group Study AALL1331